• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Syncomf Share Price

    Syncom Formulation (India) Share PriceSyncom Formulation (India)

    Small Cap 6.2k Result
    ₹9.42
    1.03 (12.28%)
    As on 04 October, 2023 | 05:41 BSE: 524470 NSE: SYNCOMFISIN: INE312C01025

    Syncom Formulation (India) Performance

    Day Range

    • Low 8.45
    • High 9.7
    9.42

    52 Week Range

    • Low 4.6
    • High 11.6
    9.42
    • Open Price8.55
    • Previous Close8.4
    • Volume16724057

    Start SIP in Syncom Formulation (India)

    Start SIP

    Syncom Formulation (India) Share Price

    • Over 1 Month 9.03%
    • Over 3 Month 25.27%
    • Over 6 Month 58.05%
    • Over 1 Year 16.58%

    Syncom Formulation (India) Key Statistics

    P/E Ratio 43
    PEG Ratio 3.3
    Market Cap Cr 886
    Price to Book Ratio 3.5
    EPS 0.2
    Dividend 0
    Relative Strength Index 68.43
    Money Flow Index 53.29
    MACD Signal 0.03
    Average True Range 0.38

    Syncom Formulation (India) Investment Rating

    • Master Rating:

    • Syncom Formulations India has an operating revenue of Rs. 232.69 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 12% is healthy, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 12% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 4% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 114 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Syncom Formulation (India) Financials
    IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 596157545158
    Operating Expenses Qtr Cr 535551504856
    Operating Profit Qtr Cr 666432
    Depreciation Qtr Cr 111111
    Interest Qtr Cr 111111
    Tax Qtr Cr 222211
    Net Profit Qtr Cr 484445
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 239232
    Operating Expenses Annual Cr 205200
    Operating Profit Annual in Cr 2019
    Depreciation Cr 54
    Interest Annual Cr 31
    Tax Annual Cr 66
    Net Profit Annual Cr 2020
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 16
    Cash from Investing Activity Annual Cr -27
    Cash from Financing Annual Activity Cr 8
    Net Cash Flow Annual Cr -2
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 256222
    Fixed Assets Annual Cr 116100
    Total Non Current Assets Annual Cr 196168
    Total Current Assets Annual Cr 181140
    Total Assets Annual Cr 377308
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 33
    ROE Annual % 89
    ROCE Annual % 1112
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1514
    IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 606157545158
    Operating Expenses Qtr Cr 535551504856
    Operating Profit Qtr Cr 666432
    Depreciation Qtr Cr 111111
    Interest Qtr Cr 111111
    Tax Qtr Cr 222211
    Net Profit Qtr Cr 484445
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 239
    Operating Expenses Annual Cr 205
    Operating Profit Annual in Cr 20
    Depreciation Cr 5
    Interest Annual Cr 3
    Tax Annual Cr 7
    Net Profit Annual Cr 20
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 256
    Fixed Assets Annual Cr 116
    Total Non Current Assets Annual Cr 196
    Total Current Assets Annual Cr 182
    Total Assets Annual Cr 378
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 3
    ROE Annual % 8
    ROCE Annual % 11
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 15

    Syncom Formulation (India) Technicals

    EMA & SMA

    Current Price
    ₹9.42
    1.03 (12.28%)
    • Bullish Moving Average
    • ___
    • 0
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹8.63
    • 50 Day
    • ₹8.41
    • 100 Day
    • ₹8.05
    • 200 Day
    • ₹7.88
    • 20 Day
    • ₹8.63
    • 50 Day
    • ₹8.5
    • 100 Day
    • ₹7.87
    • 200 Day
    • ₹7.5

    Syncom Formulation (India) Resistance and Support

    PIVOT
    ₹9.2
    Resistance
    First Resistance ₹9.91
    Second Resistance ₹10.4
    Third Resistance ₹11.11
    RSI 68.44
    MFI 53.29
    MACD Single Line 0.03
    MACD 0.06
    Support
    First Resistance ₹8.71
    Second Resistance ₹8
    Third Resistance ₹7.51

    Syncom Formulation (India) Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 19,683,204 1,062,302,520 53.97
    Week 6,400,336 345,106,090 53.92
    1 Month 3,103,826 183,994,820 59.28
    6 Month 3,191,612 180,836,740 56.66

    Syncom Formulation (India) Result Highlights

    Syncom Formulation (India) Synopsis

    NSE-Medical-Diversified

    Syncom Formul. is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 224.64 Cr. and Equity Capital is Rs. 94.00 Cr. for the Year ended 31/03/2023. Syncom Formulation (India) Ltd. is a Public Limited Listed company incorporated on 21/06/1988 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1988PLC047759 and registration number is 047759.
    Market Cap 888
    Sales 233
    Shares in Float 46.06
    No of funds 1
    Yield 1.01
    Book Value 3.47
    U/D Vol ratio 1
    LTDebt / Equity
    Alpha 0.12
    Beta 0.46

    Syncom Formulation (India)

    Owner NameJun-23Mar-23Dec-22
    Promoters 50.57%50.57%50.57%
    Mutual Funds
    Foreign Portfolio Investors
    Individual Investors 45%44.85%45.02%
    Others 4.43%4.58%4.41%

    Syncom Formulation (India) Management

    Name Designation
    Mr. Kedarmal Shankarlal Bankda Executive Chairman
    Mr. Vijay Shankarlal Bankda Managing Director
    Mrs. Rinki Ankit Bankda Whole Time Director
    Mr. Krishna Das Neema Independent Director
    Mr. Praveen Jindal Independent Director
    Mr. Vinod Kumar Kabra Independent Director
    Mrs. Ruchi Jindal Addnl. Independent Woman Director

    Syncom Formulation (India) Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Syncom Formulation (India) Corporate Action

    Date Purpose Remarks
    2023-08-14 Quarterly Results
    2023-05-29 Audited Results
    2023-02-13 Quarterly Results
    2022-11-14 Quarterly Results
    2022-08-13 Quarterly Results & Final Dividend

    Syncom Formulation (India) MF Shareholding

    Name Amount(cr)
    Motilal Oswal S&P BSE Healthcare ETF 8
    • Company Name
    • CMP
    • Chg(%)
    • Company Name
    • CMP
    • Chg(%)

    Syncom Formulation (India) FAQs

    What is Share Price of Syncom Formulation (India) ?

    Syncom Formulation (India) share price is ₹9 As on 04 October, 2023 | 05:27

    What is the Market Cap of Syncom Formulation (India) ?

    The Market Cap of Syncom Formulation (India) is ₹885.5 Cr As on 04 October, 2023 | 05:27

    What is the P/E ratio of Syncom Formulation (India) ?

    The P/E ratio of Syncom Formulation (India) is 43 As on 04 October, 2023 | 05:27

    What is the PB ratio of Syncom Formulation (India) ?

    The PB ratio of Syncom Formulation (India) is 3.5 As on 04 October, 2023 | 05:27

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.